Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Communication to Targeted Risk Assessment
General health and science communication has long served as a foundation for public understanding of medical conditions and treatment options. In this tradition, audiences have become familiar with broad concepts such as bone health, medication side effects, and the importance of informed patient-provider dialogue. This legacy context naturally includes discussions of prescription drugs used for chronic conditions, where benefit-risk assessments are standard practice. Within this framework, one specific area of clinical attention has emerged: the relationship between bisphosphonate therapy—particularly Fosamax (alendronate)—and a rare but serious condition affecting the jaw. This concern, known as osteonecrosis of the jaw, has prompted careful scrutiny in both clinical and research settings. The scientific discourse now examines whether exposure to Fosamax can be causally linked to this adverse outcome, moving beyond general health awareness into a more focused investigation of drug-specific risk. This pivot from broad health education to a targeted occupational and clinical exposure question reflects the natural evolution of medical science communication. For professionals in manufacturing, pharmacy, or healthcare settings where Fosamax handling or administration occurs, understanding this potential causation becomes a matter of occupational relevance. The transition from general health literacy to specific exposure risk assessment thus represents a logical progression in applied scientific inquiry.
Bridging to Clinical Evidence: Fosamax and ONJ
Building on the legacy of general health communication, we now turn to the specific clinical evidence connecting Fosamax to osteonecrosis of the jaw (ONJ). Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The drug works by inhibiting bone resorption, which increases bone mass and reduces the incidence of fractures, including those of the hip and spine (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ often involves pain, swelling, and exposed bone in the jaw, which may be accompanied by purulent discharge or fistula formation. Diagnosis is typically based on clinical examination and imaging, with a history of bisphosphonate exposure being a key consideration.
Mechanistic and Epidemiological Evidence
The scientific evidence connecting Fosamax to ONJ is grounded in multiple lines of investigation. First, pharmacovigilance data from the FDA Adverse Event Reporting System and clinical studies have documented cases of ONJ in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling for Fosamax explicitly states that osteonecrosis of the jaw has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Similarly, the labeling for Fosamax Plus D includes the same warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Second, mechanistic pathways have been proposed to explain how bisphosphonates like Fosamax may contribute to ONJ. Bisphosphonates inhibit osteoclast activity, which can suppress bone turnover and remodeling. In the jawbone, which undergoes high rates of remodeling due to daily mechanical stress from chewing and the presence of teeth, this suppression may impair the bone's ability to repair microdamage and respond to local infections or trauma. A multiscale characterization of jawbone in estrogen-deficient rats treated with alendronate (the active ingredient in Fosamax) provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research suggests that bisphosphonate treatment alters the mechanical and material properties of the jawbone, potentially increasing susceptibility to ONJ. Third, the timeline between exposure and documented health outcomes is variable. The time to onset of symptoms after starting Fosamax can range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
Risk Factors and Clinical Interpretation
In terms of risk factors, known contributors to ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These factors can act synergistically with bisphosphonate therapy to increase the likelihood of developing ONJ. For affected patients, a causation-focused clinical interpretation is important. While ONJ can occur spontaneously, the association with bisphosphonate use is well-documented in the medical literature and regulatory warnings. In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as bone pain or jaw issues were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, most patients who developed severe symptoms had relief after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship in susceptible individuals. The safety-communication context regarding Fosamax and ONJ is clear: the FDA-approved labeling includes a warning about this risk, and healthcare providers are advised to consider the benefits and risks of bisphosphonate therapy, especially in patients with known risk factors. For patients at low risk for fracture, the optimal duration of use has not been determined, and drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, the scientific evidence connecting Fosamax to osteonecrosis of the jaw includes clinical reports, mechanistic studies, and regulatory warnings. The risk is influenced by duration of exposure, concomitant risk factors, and individual susceptibility. Patients and clinicians should be aware of this potential adverse effect and take appropriate preventive measures, such as maintaining good oral hygiene and avoiding invasive dental procedures during bisphosphonate therapy when possible.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.
Frequently Asked Questions
What is the scientific evidence connecting Fosamax to osteonecrosis of the jaw?
The scientific evidence includes pharmacovigilance data from the FDA Adverse Event Reporting System, clinical studies documenting ONJ cases in bisphosphonate users, and mechanistic studies showing that bisphosphonates like Fosamax suppress bone turnover, impairing jawbone repair. Regulatory warnings from the FDA-approved labeling also confirm the association (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What are the risk factors for developing ONJ while taking Fosamax?
Risk factors include invasive dental procedures (tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Longer duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
How long does it take for ONJ symptoms to appear after starting Fosamax?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Free Case & Eligibility Review
Individuals with documented Fosamax exposure and a related diagnosis may request an independent, no-cost eligibility review.